NLRP3 and brain ischemia: The compound IMM-H004, a new coumarin derivative, downregulated the amount of CKLF1 binding with C–C chemokine receptor type 4, further suppressing the activation of the NLRP3 inflammasome and the following inflammatory response, thereby improving brain ischemia-reperfusion injury [128].